TY - JOUR
T1 - Autoimmune bullous diseases
T2 - Ocular manifestations and management
AU - Laforest, Caroline
AU - Huilgol, Shyamala C.
AU - Casson, Robert
AU - Selva, Dinesh
AU - Leibovitch, Igal
PY - 2005
Y1 - 2005
N2 - The ocular manifestations of autoimmune bullous diseases are common and potentially sight-threatening. Major ophthalmic involvement is most commonly seen in mucous membrane pemphigoid (cicatricial pemphigoid), epidermolysis bullosa acquisita, linear IgA bullous disease, pemphigus vulgaris and paraneoplastic pemphigus. The main pathological process is related to autoimmuneinduced conjunctival inflammation with consequent lid and corneal pathology, which may eventually result in permanent visual loss. Ocular involvement can be asymptomatic. Early detection is aided by careful attention to symptoms and signs of early ophthalmic disease. Ocular disease can be difficult to treat and management usually involves systemic therapy with immunomodulators to control inflammation and prevent progression to irreversible blindness, as well as surgical intervention in advanced disease. Recent advances in treatment, including metho-trexate, mycophenolate mofetil, monoclonal antibodies and topical tacrolimus therapies, have led to promising results.
AB - The ocular manifestations of autoimmune bullous diseases are common and potentially sight-threatening. Major ophthalmic involvement is most commonly seen in mucous membrane pemphigoid (cicatricial pemphigoid), epidermolysis bullosa acquisita, linear IgA bullous disease, pemphigus vulgaris and paraneoplastic pemphigus. The main pathological process is related to autoimmuneinduced conjunctival inflammation with consequent lid and corneal pathology, which may eventually result in permanent visual loss. Ocular involvement can be asymptomatic. Early detection is aided by careful attention to symptoms and signs of early ophthalmic disease. Ocular disease can be difficult to treat and management usually involves systemic therapy with immunomodulators to control inflammation and prevent progression to irreversible blindness, as well as surgical intervention in advanced disease. Recent advances in treatment, including metho-trexate, mycophenolate mofetil, monoclonal antibodies and topical tacrolimus therapies, have led to promising results.
UR - http://www.scopus.com/inward/record.url?scp=24344452913&partnerID=8YFLogxK
U2 - 10.2165/00003495-200565130-00003
DO - 10.2165/00003495-200565130-00003
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 16114976
AN - SCOPUS:24344452913
SN - 0012-6667
VL - 65
SP - 1767
EP - 1779
JO - Drugs
JF - Drugs
IS - 13
ER -